Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Angelalign Technology  / Equity Capital Markets

Angelalign is a leading clear aligner player in China with nearly half of the market. The company is looking to raise up to USD 300 million via a Hong Kong listing.The company provides the dentists its proprietary digital system that assists in planning the customized treatment for malocclusion patients and sells the clear aligners. We think the overall story is interesting, with an under penetrated market, a foreign player side-by-side, strong growth and solid financials. While it sells medical devices, it has a consumer element in the products that is similar to aesthetic products. The company also has a long track record for more than 10 years in the market. We think it will be a hot deal that is worth following by investors.

Angelalign is a leading clear aligner player in China with nearly half of the market. The company is looking to raise up to USD 300 million via a Hong Kong listing.The company provides the dentists its proprietary digital system that assists in planning the customized treatment for malocclusion patients and sells the clear aligners. We think the overall story is interesting, with an under penetrated market, a foreign player side-by-side, strong growth and solid financials. While it sells medical devices, it has a consumer element in the products that is similar to aesthetic products. The company also has a long track record for more than 10 years in the market. We think it will be a hot deal that is worth following by investors.

Angelalign (时代天使) Pre-IPO: Medical Device Player with Consumer Feature